Back to News
Market Impact: 0.3
Collegium Pharmaceutical Q3 Earnings Call Highlights
Source: marketbeat.com
Corporate EarningsCompany FundamentalsCorporate Guidance & OutlookHealthcare & Biotech
Collegium Pharmaceutical reported record third-quarter 2026 revenue, with growth in its ADHD portfolio offsetting declining pain-medicine sales. The company reaffirmed its full-year outlook, while quarterly earnings fell from a year earlier; the article provides no revenue or earnings figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.05
Ticker Sentiment
COLL0.45
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook